The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Total neoadjuvant therapy + pembrolizumab in locally-advanced rectal cancer
Namrata Vijayvergia, MD, Fox Chase Cancer Center, Philadelphia, PA, outlines the results of a randomized Phase II clinical trial platform using total neoadjuvant therapy in combination with pembrolizumab in patients with locally advanced rectal cancer. Pembrolizumab added to chemoradiation was safe and was not associated with unexpected short-term toxicities but did not meet the primary endpoint of improvement in Neoadjuvant Rectal Cancer (NAR) score. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
